Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion‐driven non‐small cell lung cancer

Antoine Desilets,Matteo Repetto,Alexander Drilon

DOI: https://doi.org/10.1002/ctm2.70017

IF: 8.554

2024-10-16

Clinical and Translational Medicine

Abstract:The ROS1 proto‐oncogene encodes a receptor tyrosine kinase with structural homology to other oncogenic drivers, including ALK and TRKA‐B‐C. The FDA‐approved tyrosine kinase inhibitors (TKIs) crizotinib and entrectinib have demonstrated efficacy in treating ROS1 fusion‐positive NSCLC. However, limitations such as poor blood‐brain barrier penetration and acquired resistance, particularly the ROS1 G2032R solvent‐front mutation, hinder treatment durability. Repotrectinib, a next‐generation macrocyclic TKI, was rationally designed to overcome on‐target resistance mutations and improve brain distribution through its low molecular weight. In the TRIDENT‐1 clinical trial, repotrectinib demonstrated significant efficacy in both TKI‐naïve and TKI‐pretreated patients with ROS1‐rearranged NSCLC, including those with CNS metastases and G2032R resistance mutations. In the TKI‐naïve cohort (n = 71), 79% of patients achieved an objective response, with a median progression‐free survival (PFS) of 35.7 months, surpassing all previously approved ROS1 TKIs. In patients who had received one prior ROS1 TKI but were chemotherapy‐naïve (n = 56), objective responses were observed in 38%, and median PFS was 9.0 months. The safety profile of repotrectinib was consistent with earlier‐generation ROS1 TKIs and common adverse events included anemia, neurotoxicity, increased creatine kinase levels, and weight gain. These findings underscore the potential of repotrectinib to address unmet needs in ROS1‐rearranged NSCLC, offering durable responses and improved intracranial activity. Future research should prioritize developing next‐generation, selective ROS1 inhibitors to reduce Trk‐mediated toxicities and improve treatment tolerance.

oncology,medicine, research & experimental